Page 6«..5678..2030..»

Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call

Posted: October 30, 2024 at 2:42 am

MALVERN, Pa., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release third quarter 2024 financial and operating results prior to market open on Tuesday, November 12, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

See the original post here:
Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call

Posted in Global News Feed | Comments Off on Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call

MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call

Posted: October 30, 2024 at 2:42 am

ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2024 after the market closes on Tuesday, November 5, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, November 5, 2024, at 4:30 pm ET.

Read the rest here:
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call

Posted in Global News Feed | Comments Off on MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

Posted: October 30, 2024 at 2:42 am

BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 12, 2024, to report its financial results for the second quarter ended September 30, 2024, and provide a business update.

See the original post:
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

Posted in Global News Feed | Comments Off on Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

Posted: October 30, 2024 at 2:42 am

REDWOOD CITY, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers, today reported third quarter 2024 financial results and corporate highlights.

More:
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

Posted in Global News Feed | Comments Off on Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET

Posted: October 30, 2024 at 2:42 am

HOLLISTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2024 before the market opens on November 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Read the original:
Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET

Posted in Global News Feed | Comments Off on Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET

BioAdaptives, Inc. Letter to Shareholders Regarding the Reverse Stock Split

Posted: October 30, 2024 at 2:42 am

LAS VEGAS, Oct. 29, 2024 (GLOBE NEWSWIRE) -- via IBN -- Due to a website maintenance error, a draft of a letter to BioAdaptives® (OTC: BDPT) shareholders was made available on the BioAdaptives® website. While the timing was unfortunate, it raised awareness of an upcoming event critical for the long-term health of BioAdaptives®.

Visit link:
BioAdaptives, Inc. Letter to Shareholders Regarding the Reverse Stock Split

Posted in Global News Feed | Comments Off on BioAdaptives, Inc. Letter to Shareholders Regarding the Reverse Stock Split

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and…

Posted: October 30, 2024 at 2:42 am

CAMBRIDGE, Mass. and SAN DIEGO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases.

Go here to read the rest:
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and...

Posted in Global News Feed | Comments Off on Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and…

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

Posted: October 30, 2024 at 2:42 am

CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3?), announced that it will participate in “Webinar Wednesday” hosted by Lantern Pharma on October 30, 2024.

Here is the original post:
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

Posted in Global News Feed | Comments Off on Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend

Posted: October 30, 2024 at 2:42 am

FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock.

Read the original here:
Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend

Posted in Global News Feed | Comments Off on Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend

Sandoz reports third-quarter and nine-month 2024 sales

Posted: October 30, 2024 at 2:42 am

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

The rest is here:
Sandoz reports third-quarter and nine-month 2024 sales

Posted in Global News Feed | Comments Off on Sandoz reports third-quarter and nine-month 2024 sales

Page 6«..5678..2030..»